Prime Medicine, Inc. (PRME) Stock Analysis
A live, multi-source view of Prime Medicine, Inc. (PRME): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor.
Sector: Healthcare · Industry: Biotechnology · United States · 146 employees · primemedicine.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Prime Medicine, Inc. (PRME) had a market capitalization of $671.1M (forward -4.2) and a beta of 2.35; the shares traded in a 52-week range of $2.67 – $6.94 (-4.9% over the year).
- Market cap
- $671.1M
- Enterprise value
- $675.7M
- Forward P/E
- -4.2
- Price / book
- 16.44
- EPS (trailing)
- $-1.05
- EPS (forward)
- $-0.89
- Payout ratio
- 0.0%
- 52-week range
- $2.67 – $6.94
- 52-week change
- -4.9%
- Beta
- 2.35
- Average volume
- 3.2M
- Shares outstanding
- 181.4M
- Short % of float
- 24.68%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Prime Medicine, Inc. (PRME) last closed at $3.35 (the last completed close before that scan).
Technicals at the scan: RSI 47 (neutral territory), price -2.9% versus its 20-day average, 20-day versus 50-day average spread +2.1%, MACD histogram -0.02.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 71/100.
Next scheduled company event: in 56 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for PRME in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
PRME has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Prime Medicine, Inc. (PRME) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PRME.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.